Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Maintains Buy on Nutanix, Raises Price Target to $71

Needham analyst Jack Andrews maintains Nutanix (NASDAQ:NTNX) with a Buy and raises the price target from $64 to $71.

byBenzinga Newsdesk

November 24, 2021

1 minute read

Needham analyst Jack Andrews maintains Nutanix (NASDAQ:NTNX) with a Buy and raises the price target from $64 to $71.

News

Smaller U-haul Store In Edmond To Close After Larger Center Opens Nearby; To Let Go Of Eight Team Members

By Benzinga Newsdesk

Today, 9:41 AM

The U-Haul® store at 610 S. Broadway in Edmond will end its lease and close its doors on Feb. 4 after 12 years of serving the local community. The facility has been open since 2011. Eight Team

UHAL

News

U.S. Holiday Sales Up 8.5% From Last Year Despite Omicron And Supply Chain Issues: Report

By Michael Cohen

Today, 9:41 AM

A new report shows U.S. holiday sales jumped by 8.5% as compared to last year, increasing at the fastest rate in 17 years.

Cooper Companies Q2 EPS $3.24 Misses $3.43 Estimate

By Benzinga Newsdesk

Today, 9:41 AM

Cooper Companies (NYSE:COO) reported quarterly earnings of $3.24 per share which missed the analyst consensus estimate of $3.43 by 5.54 percent. This is a 4.14 percent decrease over earnings of $3.38 per share from the

COO

Karyopharm Plans To Initiate New Placebo-Controlled Randomized Study Of Selinexor Following FDA Discussion

By Bill Haddad

Today, 9:41 AM

Following Discussion with the FDA, Karyopharm Plans to Initiate a New Placebo-Controlled Randomized Study of Selinexor in the Advanced or Recurrent Endometrial Cancer p53 Wild-Type Population to Support a Future sNDA

KPTI

Needham Maintains Buy on Nutanix, Raises Price Target to $71

Related Posts

Smaller U-haul Store In Edmond To Close After Larger Center Opens Nearby; To Let Go Of Eight Team Members

U.S. Holiday Sales Up 8.5% From Last Year Despite Omicron And Supply Chain Issues: Report

Cooper Companies Q2 EPS $3.24 Misses $3.43 Estimate

Karyopharm Plans To Initiate New Placebo-Controlled Randomized Study Of Selinexor Following FDA Discussion